Sanofi acquires Blueprint for $9.1 billion

The shopping spree of the big international pharmaceutical groups continues. The latest deal announced is Sanofi's acquisition of Blueprint Medicines for a total equity value of $9.1 billion. The deal is part of the French group's strategy to expand its drug portfolio dedicated to rare immunological diseases.

In PArigi, Sanofi's stock trades down less than half a percentage point, while Wall Street trading is expected to open for the US biotech. In pre-market trading, it gained more than 26 per cent in line with the offer price.

The deal calls for a cash consideration of $129 per share, representing a 27% premium over Blueprint's closing share price on Friday. Shareholders of the US biotech will also receive a non-negotiable contingent value right (CVR), which could yield an additional $2 or $4 per share upon the achievement of certain regulatory and clinical development milestones related to BLU-808, an investigational therapy for mast cell disorders, including chronic urticaria.

Including potential CVR-related payments, the transaction reaches a total value of approximately USD 9.5 billion on a fully diluted basis. Sanofi expects to finalise the acquisition in the third quarter of 2025 and has indicated that the transaction will not significantly affect its financial outlook for the year.

The acquisition is part of Sanofi's broader goal to establish itself as a leader in immunology. Earlier this year, the French group had already signed a $1.9 billion deal with Dren Bio to acquire a drug against autoimmune diseases. Regarding this latest deal, Sanofi emphasises that the acquisition of Blueprint brings with it a promising pipeline of immunological drugs under development and a strong network of relationships with specialists in the field.